Michael A Quigley

US Patent:

20210395392, Dec 23, 2021

Filed:

Oct 8, 2019

Appl. No.:

17/284119

Inventors:

- Princeton NJ, US
Michael Quigley - San Carlos CA, US
Virginie Lafont - Lawrence Twp NJ, US
Ginger C. Rakestraw - Somerville MA, US
Linda Liang - Mountain View CA, US

International Classification:

C07K 16/40
A61K 47/68
A61P 35/00
C07K 16/28

Abstract:

This disclosure provides isolated antibodies that bind specifically to MerTK expressed on the surface of a cell and inhibit efferocytosis by the MerTK-expressing cell. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-MerTK antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1 or anti-PD-L1 antibody.

US Patent:

20210277135, Sep 9, 2021

Filed:

Jul 12, 2019

Appl. No.:

17/259969

Inventors:

- Princeton NJ, US
Michael QUIGLEY - San Carlos CA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07K 16/28
G01N 33/574
A61P 35/00

Abstract:

Provided are methods for clinical treatment of malignant tumors (e.g., advanced solid tumors) using a combination of an OX40 agonist, a PD-1 pathway inhibitor, and a CTLA-4 inhibitor.

US Patent:

20200399385, Dec 24, 2020

Filed:

Apr 13, 2020

Appl. No.:

16/847130

Inventors:

- Princeton NJ, US
Indrani CHAKRABORTY - Fremont CA, US
Marie-Michelle Navarro GARCIA - San Jose CA, US
Thomas D. KEMPE - Sunnyvale CA, US
Alan J. KORMAN - Piedmont CA, US
Alexander T. KOZHICH - Princeton NJ, US
Hadia LEMAR - Tracy CA, US
Mark MAURER - Seattle WA, US
Christina Maria MILBURN - Santa Cruz CA, US
Michael QUIGLEY - Ambler PA, US
Xiang SHAO - Milpitas CA, US
Mohan SRINIVASAN - Cupertino CA, US
Kent THUDIUM - Oakland CA, US
Susan Chien-Szu WONG - Fremont CA, US
Jochem GOKEMEIJER - Wayland MA, US
Xi-Tao WANG - Wellesley MA, US
Han CHANG - West Windsor NJ, US
Patrick GUIRNALDA - Framingham MA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07K 16/28
C07K 16/30
A61P 35/00
A61K 39/395
G01N 33/574

Abstract:

Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

US Patent:

20200369777, Nov 26, 2020

Filed:

Nov 1, 2018

Appl. No.:

16/760776

Inventors:

- Princeton NJ, US
Chan GAO - Redwood City CA, US
Michael QUIGLEY - Ambler PA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07K 16/28
A61P 35/00
G01N 33/574
A61K 9/00

Abstract:

Provided herein are methods of treating cancer using agonistic antibodies that specifically bind to immunostimulatory receptors, wherein the antibodies are administered in an amount and/or frequency sufficient to achieve and/or maintain a receptor occupancy of less than about 80%, for example, a receptor occupancy of about 20% to about 80%. Also provided are methods of determining human doses for such agonistic antibodies, and methods for monitoring receptor occupancy of the agonistic antibodies in order to maintain effective antibody levels in, e.g., human patients. Also provided are methods of measuring soluble OX40 in a subject. Also provided are methods of treating cancer, comprising administering to the subject an effective amount of each of an anti-OX40 antibody and an anti-PD-1 antibody.

US Patent:

20200207816, Jul 2, 2020

Filed:

Jan 8, 2020

Appl. No.:

16/737745

Inventors:

- Princeton NJ, US
Alan J. KORMAN - Piedmont CA, US
Michael QUIGLEY - San Carlos CA, US
Mark J. SELBY - San Francisco CA, US
Changyu WANG - Union City CA, US

International Classification:

C07K 14/435
C07K 16/28
A61P 35/00

Abstract:

The present disclosure provides a method for enhancing the anti-tumor efficacy of an Fc fusion protein which binds specifically to a target, e.g., a co-inhibitory or co-stimulatory receptor of ligand, on a T cell in a subject afflicted with a cancer or a disease caused by an infectious agent and alters the activity of the immunomodulatory target, thereby potentiating an endogenous immune response against cells of the cancer or the infectious agent, wherein the method comprises selecting, designing or modifying the Fc region of the Fc fusion protein so as to enhance the binding of said Fc region to an activating Fc receptor (FcR). The disclosure also provides an Fc fusion protein produced by said method and its use in treating a subject afflicted with a cancer or a disease caused by an infectious agent.

US Patent:

20180312553, Nov 1, 2018

Filed:

Feb 13, 2018

Appl. No.:

15/895655

Inventors:

- Princeton NJ, US
Alan J. KORMAN - Piedmont CA, US
Michael QUIGLEY - Ambler PA, US
Mark J. SELBY - San Francisco CA, US
Changyu WANG - Union City CA, US

International Classification:

C07K 14/435
C07K 16/28

Abstract:

The present disclosure provides a method for enhancing the anti-tumor efficacy of an Fc fusion protein which binds specifically to a target, e.g., a co-inhibitory or co-stimulatory receptor of ligand, on a T cell in a subject afflicted with a cancer or a disease caused by an infectious agent and alters the activity of the immunomodulatory target, thereby potentiating an endogenous immune response against cells of the cancer or the infectious agent, wherein the method comprises selecting, designing or modifying the Fc region of the Fc fusion protein so as to enhance the binding of said Fc region to an activating Fc receptor (FcR). The disclosure also provides an Fc fusion protein produced by said method and its use in treating a subject afflicted with a cancer or a disease caused by an infectious agent.

US Patent:

20180237534, Aug 23, 2018

Filed:

May 26, 2016

Appl. No.:

15/577375

Inventors:

- Princeton NJ, US
Indrani CHAKRABORTY - Fremont CA, US
Marie-Michelle Navarro GARCIA - San Jose CA, US
Thomas D. KEMPE - Sunnyvale CA, US
Alan J. KORMAN - Piedmont CA, US
Alexander T. KOZHICH - Princeton NJ, US
Hadia LEMAR - Tracy CA, US
Mark MAURER - Seattle WA, US
Christina Maria MILBURN - Santa Cruz CA, US
Michael QUIGLEY - Ambler PA, US
Maria RODRIGUEZ - San Jose CA, US
Xiang SHAO - Milpitas CA, US
Mohan SRINIVASAN - Cupertino CA, US
Brenda L. STEVENS - Seattle WA, US
Kent THUDIUM - Oakland CA, US
Susan Chien-Szu WONG - Fremont CA, US
Jochem GOKEMEIJER - Wayland MA, US
Xi-Tao WANG - Wellesley MA, US
Han CHANG - West Windsor NJ, US
Christine HUANG - Princeton NJ, US
Zheng YANG - Plainsboro NJ, US
Yan FENG - Pittsburgh PA, US
Patrick GUIRNALDA - Framingham MA, US
Nils LONBERG - Woodside CA, US
Bryan C. BARNHART - Philadelphia PA, US
Aaron P. YAMNIUK - Lawrenceville NJ, US
Karla A. HENNING - Milpitas CA, US
Michelle Minhua HAN - Piedmont CA, US
Ming LEI - Princeton NJ, US
Liang SCHWEIZER - Shanghai PR, CN
Sandra V. HATCHER - Hillsborough NJ, US
Arvind RAJPAL - San Francisco CA, US
Mark J. SELBY - San Francisco CA, US

International Classification:

C07K 16/28
C07K 16/30
A61K 39/395
G01N 33/574
A61P 35/00

Abstract:

Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

US Patent:

20170306035, Oct 26, 2017

Filed:

Mar 30, 2017

Appl. No.:

15/474731

Inventors:

- Princeton NJ, US
Indrani CHAKRABORTY - Fremont CA, US
Marie-Michelle Navarro GARCIA - San Jose CA, US
Thomas D. KEMPE - Sunnyvale CA, US
Alan J. KORMAN - Piedmont CA, US
Alexander T. KOZHICH - Princeton NJ, US
Hadia LEMAR - Tracy CA, US
Mark MAURER - Seattle WA, US
Christina Maria MILBURN - Santa Cruz CA, US
Michael QUIGLEY - Ambler PA, US
Xiang SHAO - Milpitas CA, US
Mohan SRINIVASAN - Cupertino CA, US
Kent THUDIUM - Oakland CA, US
Susan Chien-Szu WONG - Fremont CA, US
Jochem GOKEMEIJER - Wayland MA, US
Xi-Tao WANG - Wellesley MA, US
Han CHANG - West Windsor NJ, US
Patrick GUIRNALDA - Framingham MA, US

International Classification:

C07K 16/28
C07K 16/30
C07K 16/30
C07K 16/30
C07K 16/30
A61K 39/00
C07K 16/28
A61K 39/00

Abstract:

Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.